Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Ann Surg ; 279(1): 119-124, 2024 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-37212166

RESUMO

OBJECTIVE: To identify risk factors associated with the progression of pancreatic cysts in patients undergoing surveillance. BACKGROUND: Previous studies of intraductal papillary mucinous neoplasms (IPMNs) rely on surgical series to determine malignancy risk and have inconsistently identified characteristics associated with IPMN progression. METHODS: We conducted a retrospective review of 2197 patients presenting with imaging concerning for IPMN from 2010 to 2019 at a single institution. Cyst progression was defined as resection or pancreatic cancer development. RESULTS: The median follow-up time was 84 months from the presentation. The median age was 66 years, and 62% were female. Ten percent had a first-degree relative with pancreatic cancer, and 3.2% had a germline mutation or genetic syndrome associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC). Cumulative incidence of progression was 17.8% and 20.0% at 12 and 60 months postpresentation, respectively. Surgical pathology for 417 resected cases showed noninvasive IPMN in 39% of cases and PDAC with or without associated IPMN in 20%. Only 18 patients developed PDAC after 6 months of surveillance (0.8%). On multivariable analysis, symptomatic disease [hazard ratio (HR)=1.58; 95% CI: 1.25-2.01], current smoker status (HR=1.58; 95% CI: 1.16-2.15), cyst size (HR=1.26; 95% CI: 1.20-1.33), main duct dilation (HR=3.17; 95% CI: 2.44-4.11), and solid components (HR=1.89; 95% CI: 1.34-2.66) were associated with progression. CONCLUSIONS: Worrisome features on imaging at presentation, current smoker status, and symptomatic presentation are associated with IPMN progression. Most patients progressed within the first year of presentation to Memorial Sloan Kettering Cancer Center (MSKCC). Further investigation is necessary to develop personalized cyst surveillance strategies.


Assuntos
Carcinoma Ductal Pancreático , Cisto Pancreático , Neoplasias Intraductais Pancreáticas , Neoplasias Pancreáticas , Humanos , Feminino , Idoso , Masculino , Neoplasias Intraductais Pancreáticas/patologia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/epidemiologia , Neoplasias Pancreáticas/cirurgia , Carcinoma Ductal Pancreático/diagnóstico , Carcinoma Ductal Pancreático/epidemiologia , Carcinoma Ductal Pancreático/cirurgia , Fatores de Risco , Cisto Pancreático/diagnóstico por imagem , Cisto Pancreático/cirurgia , Estudos Retrospectivos
3.
Dig Dis Sci ; 66(5): 1631-1638, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-32445049

RESUMO

GOALS AND BACKGROUND: Ustekinumab (UST) is a monoclonal antibody inhibitor of IL-12/IL-23 approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). We conducted a meta-analysis to compare rates of adverse events (AEs) in randomized controlled trials (RCTs) of UST for all indications. STUDY: A systematic search was performed of MEDLINE, Embase, and PubMed databases through November 2019. Study inclusion included RCTs comparing UST to placebo or other biologics in patients aged 18 years or older with a diagnosis of an autoimmune condition. RESULTS: Thirty RCTs with 16,068 patients were included in our analysis. Nine thousand six hundred and twenty-six subjects were included in the UST vs placebo analysis. There was no significant difference in serious or mild/moderate AEs between UST and placebo with an OR of 0.83 (95% CI 0.66, 1.05) and 1.08 (95% CI 0.99, 1.18), respectively, over a median follow-up time of 16 weeks. In a sub-analysis of CD and UC trials, no difference in serious or mild/moderate AEs in UST versus placebo was seen. CONCLUSIONS: UST was not associated with an increase in short-term risk of AEs.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Imunossupressores/uso terapêutico , Ustekinumab/uso terapêutico , Adulto , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/imunologia , Doença de Crohn/diagnóstico , Doença de Crohn/imunologia , Feminino , Humanos , Imunossupressores/efeitos adversos , Masculino , Pessoa de Meia-Idade , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Ustekinumab/efeitos adversos
4.
Gastrointest Endosc ; 93(3): 682-690.e4, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-32961243

RESUMO

BACKGROUND AND AIMS: Data on colorectal EMR (C-EMR) training are lacking. We aimed to evaluate C-EMR training among advanced endoscopy fellows (AEFs) by using a standardized assessment tool (STAT). METHODS: This multicenter prospective study used a STAT to grade AEF training in C-EMR during their 12-month fellowship. Cumulative sum analysis was used to establish learning curves and competence for cognitive and technical components of C-EMR and overall performance. Sensitivity analysis was performed by varying failure rates. AEFs completed a self-assessment questionnaire to assess their comfort level with performing C-EMR at the completion of their fellowship. RESULTS: Six AEFs (189 C-EMRs; mean per AEF, 31.5 ± 18.5) were included. Mean polyp size was 24.3 ± 12.6 mm, and mean procedure time was 22.6 ± 16.1 minutes. Learning curve analyses revealed that less than 50% of AEFs achieved competence for key cognitive and technical C-EMR endpoints. All 6 AEFs reported feeling comfortable performing C-EMR independently at the end of their training, although only 2 of them achieved competence in their overall performance. The minimum threshold to achieve competence in these 2 AEFs was 25 C-EMRs. CONCLUSIONS: A relatively low proportion of AEFs achieved competence on key cognitive and technical aspects of C-EMR during their 12-month fellowship. The relatively low number of C-EMRs performed by AEFs may be insufficient to achieve competence, in spite of their self-reported readiness for independent practice. These pilot data serve as an initial framework for competence threshold, and suggest the need for validated tools for formal C-EMR training assessment.


Assuntos
Neoplasias Colorretais , Gastroenterologia , Competência Clínica , Neoplasias Colorretais/cirurgia , Gastroenterologia/educação , Humanos , Curva de Aprendizado , Estudos Prospectivos
5.
Aliment Pharmacol Ther ; 49(6): 654-663, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30706496

RESUMO

BACKGROUND: Gallbladder dyskinesia (gallbladder spasm, biliary dyskinesia or chronic acalculous cholecystitis) is a poorly defined entity which presents as biliary-type pain without any identifiable organic pathology. Abnormal gallbladder ejection fraction (GBEF) is used by some to select those likely to benefit from cholecystectomy. The validity of this approach has been questioned. AIM: To systematically review the literature and summarise the evidence surrounding the practice of cholecystectomy based on GBEF for gallbladder dyskinesia. METHODS: We conducted a systematic search of PubMed/MEDLINE and SCOPUS from 1980 to 2016 to identify the relevant literature. RESULTS: Twenty-nine studies including 2891 patients were included in the final analysis. In comparing cholecystectomy with medical management, patients with a normal GBEF did not benefit from cholecystectomy; whereas those with low GBEF had a higher chance (RR, relative risk = 2.37) of symptomatic improvement following surgery. When those classified as "low" and "normal" GBEF were compared in terms of outcome following cholecystectomy, the rate of improvement following surgery was similar in the two groups (RR 1.09) which suggests a placebo effect of surgery. CONCLUSIONS: While a low GBEF may provide some guidance in identifying those with gallbladder dyskinesia who may benefit from cholecystectomy, the available data are inconsistent and based on studies of poor quality which are often subject to bias and the impact of confounding factors. For these reasons, we conclude that the role of scintigraphy and cholecystectomy in the definition and management of this disorder remain unclear pending definitive study.


Assuntos
Discinesia Biliar/cirurgia , Colecistectomia/métodos , Doenças da Vesícula Biliar/cirurgia , Esvaziamento da Vesícula Biliar/fisiologia , Discinesia Biliar/fisiopatologia , Colecistectomia/tendências , Vesícula Biliar/fisiologia , Vesícula Biliar/cirurgia , Doenças da Vesícula Biliar/fisiopatologia , Humanos , Cintilografia/métodos , Estudos Retrospectivos , Volume Sistólico
6.
Transl Vis Sci Technol ; 8(1): 4, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30627479

RESUMO

PURPOSE: This study was conducted to investigate changes in intraocular pressure (IOP) in the presence of intravitreal gas bubbles in individuals who travel through subsea tunnels. METHODS: Using a mathematical model, we simulated alterations in ocular globe shape, aqueous humor flow, volume of intravitreal gas bubbles, and IOP due to elevation changes during travel through subsea tunnels. We simulated five tunnels with different features as case studies. The role of key modeling parameters was further evaluated in a parametric study. RESULTS: In three out of the five simulated tunnels (i.e., Seikan Tunnel, Bomlafjord Tunnel, and the Atlantic Ocean Tunnel), the patients were potentially at risk at lower portions of the tunnels since the IOP dropped to values less than 5 mm Hg, the clinical threshold for ocular hypotony. During ascent, the IOP increased to the normal value of 15 mm Hg and in some cases to higher values (e.g., a peak value of 22 mm Hg in Seikan Tunnel). CONCLUSIONS: Our model predicted that in the presence of intravitreal gas bubbles, the IOP could drop to extremely low values when patients descend to lower elevations in some tunnels. Such low IOP values could cause bleeding and/or retinal detachment. Since many factors (e.g., tunnel specifications and/or patient-specific characteristics) could affect the IOP during subsea travel, caution (beyond avoiding airplane flights) should be taken in advising patients about travel restrictions following intravitreal gas injections. TRANSLATIONAL RELEVANCE: Our findings highlight the potential risk for hypotony in the presence of intravitreal gas bubbles during subsea travels.

7.
J Clin Rheumatol ; 25(1): 45-49, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29794876

RESUMO

OBJECTIVES: Avascular necrosis (AVN) is associated with significant morbidity potentially causing severe pain and disability; patients with inflammatory bowel disease (IBD) have a higher prevalence of AVN compared with non-IBD populations. The purpose of our study was to determine the prevalence of AVN in our IBD population and to evaluate these subjects for the presence of clinical characteristics associated with AVN on computed tomography (CT) imaging. METHODS: In 1313 IBD patients with abdomen/pelvis CT scans, we identified 27 patients (2.1%) with CT findings consistent with AVN. Through historical chart review, we confirmed that most patients had prior exposure to steroids, although 2 patients had no documented steroid exposure at all. RESULTS: We found that 59% of the concurrent radiology reports did not comment on the presence of AVN, suggesting that incidental CT findings of AVN among IBD patients are likely underreported. Notably, we found that 63% of these cases had documented complaints of low-back and/or hip pain. Using logistic regression, we found an association between anti-neutrophil cytoplasmic antibody-positive status across IBD (p = 0.007) and a smoking history in Crohn disease (p = 0.03) with the presence of AVN. CONCLUSIONS: We found that a significant proportion of IBD patients with AVN are reported in their records as having hip or low-back pain, and review of CT imaging under dedicated bone windows may identify AVN among this population. Our findings also suggest that additional etiological factors, beyond corticosteroids, contribute to the development of AVN in IBD. Further investigation is warranted regarding the mechanisms associated with AVN in IBD.


Assuntos
Doenças Inflamatórias Intestinais/complicações , Osteonecrose/epidemiologia , Ossos Pélvicos , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Criança , Estudos de Coortes , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Osteonecrose/diagnóstico por imagem , Prevalência , Tomografia Computadorizada por Raios X , Adulto Jovem
8.
Methodist Debakey Cardiovasc J ; 11(3): 189-91, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26634029

RESUMO

Synthetic cannabinoids (SCs) are herbal blends that use plant material with varying concentrations of synthetic analogues of cannabinoids. These products are sold as incense or potpourri and are labeled "Not for human use." Even so, rates of abuse are rapidly increasing worldwide, especially in the young adult population. An extensive network of users exists, and the products can easily be ordered on the Internet under various brand names, including the most popular ones, "K2" and "Spice." Not much is known about their spectrum of toxicity and no specific antidote is available at present. Renal failure is a rare complication associated with SC abuse. We describe a case of acute kidney injury associated with use of SCs and present a review of the current literature, including the history and some key pharmacologic and epidemiologic findings related to synthetic cannabinoid compounds.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Canabinoides/efeitos adversos , Drogas Ilícitas/efeitos adversos , Abuso de Maconha/complicações , Fumar Maconha/efeitos adversos , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/terapia , Adulto , Canabinoides/síntese química , Humanos , Drogas Ilícitas/síntese química , Exposição por Inalação , Masculino , Diálise Renal , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA